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Porphyromonas gingivalis (P. gingivalis) and Fusobacterium nucleatum (F. nucleatum) are Gram-negative anaerobic bacteria
possessing several virulence factors that make them potential pathogens associated with periodontal disease. Periodontal
diseases are chronic inﬂammatory diseases of the oral cavity, including gingivitis and periodontitis. Periodontitis can lead to
tooth loss and is considered one of the most prevalent diseases worldwide. P. gingivalis and F. nucleatum possess virulence
factors that allow them to survive in hostile environments by selectively modulating the host’s immune-inﬂammatory response,
thereby creating major challenges to host cell survival. Studies have demonstrated that bacterial infection and the host immune
responses are involved in the induction of periodontitis. The NLRP3 inﬂammasome and its eﬀector molecules (IL-1β and
caspase-1) play roles in the development of periodontitis. We and others have reported that the purinergic P2X7 receptor
plays a role in the modulation of periodontal disease and intracellular pathogen control. Caspase-4/5 (in humans) and
caspase-11 (in mice) are important eﬀectors for combating bacterial pathogens via mediation of cell death and IL-1β release.
The exact molecular events of the host’s response to these bacteria are not fully understood. Here, we review innate and
adaptive immune responses induced by P. gingivalis and F. nucleatum infections and discuss the possibility of manipulations of
the immune response as therapeutic strategies. Given the global burden of periodontitis, it is important to develop therapeutic
targets for the prophylaxis of periodontopathogen infections.

1. Introduction
Oral bacteria in dental bioﬁlms contribute to the initiation
and progression of periodontal diseases (PD) via exacerbated
host inﬂammatory responses to these bacteria [1, 2]. PD
are chronic inﬂammatory diseases of the periodontium
(supporting structures around the teeth: gingiva, periodontal
ligaments, and alveolar bone [3]), including gingivitis and
periodontitis. Gingivitis is the initial reversible inﬂammatory
lesion in the soft tissues surrounding the teeth, and periodontitis results from a combination of factors that leads to
periodontium destruction, often causing irreversible bone
resorption and tooth loss [3]. It aﬀects nearly half of the

United States population [4], and severe periodontitis is the
6th most prevalent disease worldwide [5]. Periodontitis has
a high impact on public health because of its long and expensive treatment. Furthermore, periodontitis is associated with
several systemic diseases, including diabetes mellitus, cardiovascular diseases, and atherosclerosis, as we and others
reviewed elsewhere [6, 7].
In healthy individuals, there is an established homeostasis between immunity and oral cavity microorganisms that
do not cause diseases [8]. Oral epithelial and immune cells
contribute directly and indirectly to maintain this equilibrium [9]. The loss of homeostasis due to dental plaque formation along with genetic, hormonal, and host behavioral
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factors make the individual susceptible to PD. Furthermore,
the absence or decrease of an eﬀective innate immune
response by some cells stimulated by P. gingivalis LPS can
greatly increase the proliferation of various bacterial species
with the formation of bioﬁlms at the root of the tooth, leading
to exacerbated inﬂammation in the tissues [10].
P. gingivalis, a nonmotile, non-spore-forming Gramnegative bacterium, has the ability to induce dysbiosis in
the oral microbiota (an imbalance among microbial species)
[3, 11, 12]. F. nucleatum is one of the most common species
in the human gingival sulcus; its prevalence increases with
the severity of PD and the progression of inﬂammation
[13, 14]. F. nucleatum serves as a true bridge, connecting
initial and later bacterial colonizers, thereby favoring the
formation of dental plaques [15]. When F. nucleatum is
not present, the number of late colonizers is signiﬁcantly
lower [15].
Conventional clinical treatment for periodontitis consists
initially of mechanical bacterial removal (scaling and root
planning), thereby reducing the contact of bacterial agents
with inﬂammatory and noninﬂammatory cells in the oral
cavity. However, this procedure may not be suﬃcient to
generate clinical improvement. In this context, several signaling pathways are involved in the progression of PD;
therefore, therapies that modulate these pathways may
help prevent the development of PD and consequently
avoid bone loss [16].
The exact molecular host response events against P.
gingivalis and F. nucleatum are not fully understood; nevertheless, understanding of these mechanisms is essential
for the identiﬁcation of therapeutic targets aiming to prevent
and treat periodontitis. In this context, there are some immunological pathways that have been demonstrated to be
involved in the development of periodontitis and in infections with periodontopathogens. In this respect, we and
others previously demonstrated the role of the NLRP3
inﬂammasome in the development of periodontitis [17, 18].
Furthermore, it is known that purinergic signaling via the
P2X7 receptor is one of the important pathways for the activation of the NLRP3 inﬂammasome and control of intracellular infections, including P. gingivalis infections [19, 20].
The activation of this inﬂammasome leads to caspase-1 maturation, in turn leading to cleavage of the inactive form of
interleukin- (IL-) 1β (pro-IL-1β) to its active form (IL-1β)
[21]. Cytokine production is central to the host inﬂammatory
response during PD and infection [20]. Other caspases
involved in inﬂammation, although less studied and considered involved in the noncanonical inﬂammasome, are caspase-4, caspase-5, and caspase-11 that are important factors
for counteracting Gram-negative bacterial pathogens via
induction of cell death and IL-1 release [22, 23].
This review is aimed at illuminating advances in the
study of mechanisms of innate and adaptive immune
responses after P. gingivalis and F. nucleatum interactions
with the host. We discuss the role of TLRs, the inﬂammasome, purinergic signaling, cytokines, and chemokines, as
well as the innate and adaptive immune cells involved in host
resistance to infections by these bacteria. Our review highlights the importance of understanding signaling pathways
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induced by P. gingivalis and F. nucleatum that could
potentially serve as eﬀective strategies for treating patients
with PD.

2. Porphyromonas gingivalis and
Fusobacterium nucleatum:
Periodontopathogenic Pathogens
P. gingivalis is a well-adapted colonizing opportunistic pathogen with the ability to invade gingival epithelial cells [24],
periodontal ligament ﬁbroblasts [1], osteoblasts [25], and
immune cells [26]. It requires anaerobic conditions for
growth in vitro, as well as hemin and vitamin K in its nutrient
medium. It appears as black-pigmented colonies in blood
agar medium attributed to agglomeration of heme groups
on its cell membranes [27, 28]. P. gingivalis obtains energy
through the fermentation of amino acids, thereby allowing
survival in periodontal pockets, where there are low sugar
levels [11]. P. gingivalis is considered an “inﬂammo-philic”
bacterium (from the Greek suﬃx -philic meaning “attracted
to” or “loving”) [29]; it is thought that infections with this
organism induce the production of proinﬂammatory cytokines that damage the host tissue, promoting bacterial
survival [30, 31]. Therefore, the conditions of the inﬂamed
tissue favors the nutritional needs of the dysbiotic community, caused by the release of products resulting from tissue
destruction, including peptides and components containing
heme groups [1, 19, 32]. P. gingivalis is normally found in
10%–25% of healthy subjects and 79%–90% of subjects with
periodontitis [33, 34]. There is a positive correlation between
the depth of the periodontal pocket and the presence of P.
gingivalis [11].
P. gingivalis is considered the keystone pathogen of PD
because of its ability to modify the normal oral microbiota
composition to one with greater pathogenicity that intensively accelerates bone loss [3, 35]. This periodontopathogen
is considered a master of immune system subversion that
exploits several sabotage tactics allowing it to evade, weaken,
or deceive the host’s immune system [36]. P. gingivalis
possesses several virulence factors, including proteolytic
enzymes (e.g., gingipains), capsule, lipopolysaccharide
(LPS), ﬁmbriae, nucleoside diphosphate kinase (NDK),
ceramide, and outer membrane vesicles (OMVs) [37] (summarized in Table 1).
In a classic study, Socransky et al. analyzed over 13,000
periodontitis subgingival dental plaque samples and grouped
the species into bacterial “complexes,” according to the
relationship between the diﬀerent species. The “red complex”
is constituted by P. gingivalis, Treponema denticola, and
Tannerella forsythia, presenting greater pathogenic potential, and being related to clinical measures of periodontal
disease such as pocket depth and bleeding on probing. F.
nucleatum is part of the “orange complex,” which is a core
group that supports colonization of the “red complex”
bacteria and is important for the progression of PD [38].
F. nucleatum is a human pathogen that is ﬁlamentous,
Gram-negative, non-spore-forming, nonmotile, and anaerobic [13]. It is a heterogeneous species that belongs to the
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Table 1: Virulence factors of Porphyromonas gingivalis.

Periodontopathogenic
pathogen

Virulence factors

Gingipains

Capsule (CPS or K-antigen)

Porphyromonas
gingivalis

Fimbriae

Lipopolysaccharide (LPS)
Outer membrane
vesicles (OMVs)
Nucleoside diphosphate
kinase (NDK)
Phosphoethanolamine
dihydroceramide (PEDHC)
and phosphoglycerol
dihydroceramide (PGDHC)

Serine phosphatase

Function

Reference

(i) Activates host MMPs; degrades cell-cell components, complement
system proteins, cytokines, immunoglobulins, integrins, and
collagen; alters cell signal transduction and cellular function
(ii) Cleaves T-cell receptors, including CD2, CD4, and CD8 and
interferes with the cell-mediated immune response. Cleaves
CD14, an endotoxin receptor, resulting in hyporresponsiveness
[11, 56–61]
to LPS
(iii) Stimulates the expression of protease-activated receptors on
neutrophils, gingival epithelial cells, gingival ﬁbroblasts, and T
cells, releasing proinﬂammatory cytokines, to increase vascular
permeability and to cause bleeding at the periodontal site and
inﬂux of polymorphonuclear leukocytes and degrade ﬁbrinogen
(i) Various serotypes of CPS diﬀerentially stimulate the release of
chemokines by macrophages as well as cytokines by dendritic cells
(ii) Encapsulated strains of P. gingivalis can also generate greater
[62–64]
resistance to phagocytosis by polymorphonuclear leukocytes and
diﬀerential capacity to adhere to the gingival epithelium
(i) Favor adherence to saliva proteins, to the extracellular matrix,
to eukaryotic cells, and to other bacteria, contributing to the
[65–67]
bioﬁlm generation
(ii) Type I ﬁmbriae act on the capacity for invasion and colonization.
Type II ﬁmbriae shows greater proinﬂammatory eﬃciency
(i) Stimulates proinﬂammatory responses and bone resorption
[68, 69]
(i) The puriﬁed OMVs of P. gingivalis activates the production of
proinﬂammatory cytokines, signaling of inﬂammasome, and
[70]
pyroptosis in macrophages
(i) Responsible for modulating purinergic signaling and inhibiting
[71]
proapoptotic actions of primary oral epithelial cells
(i) Promotes IL-1β-mediated release of prostaglandin E2 (PGE2) in
primary cultures of gingival ﬁbroblasts; induces apoptosis in
chondrocytes and gingival ﬁbroblasts; promotes osteoclastogenesis
[72]
mediated by receptor activator of nuclear factor kappa-Β ligand
(RANKL) via interaction with Myh9 (nonmuscle myosin II-A)
independently of Toll-like receptor 2/4 (TLR2/4)
(i) Involved in neutrophil subversion by causing dephosphorylation
of the serine S536 of the p65 subunit of NF-κB and prevents
[73–75]
translocation of NF-κB to the nucleus, consequently inhibiting
IL-8 production

Arg-X: arginine-speciﬁc; CPS: capsule; IgG: immunoglobulin G; LPS: lipopolysaccharide; Lys-X: lysine-speciﬁc; MMPs: metalloproteinases; Myh9: nonmuscle
myosin II-A; NDK: nucleoside diphosphate kinase; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; OMVs: outer membrane vesicles;
PAMPs: molecular pattern associated with the pathogen; PEDHC: phosphoethanolamine dihydroceramide; PGDHC: phosphoglycerol dihydroceramide;
PGE2: prostaglandin E2; p65: also known as Rel A, nuclear factor NF-kappa-B p65 subunit; RANKL: receptor activator of nuclear factor kappa-Β ligand;
TLR2/4: Toll-like receptor 2/4.

family Fusobacteriaceae and includes ﬁve proposed subspecies (ss): ss animalis, ss fusiforme, ss nucleatum, ss polymorphum, and ss vincentii [13, 39–41]. Despite the fact that F.
nucleatum has been found in various tissues, the most
common anatomical site in humans is the oral cavity
[13]. As for P. gingivalis, this bacterium also presents virulence factors that make it a potential opportunistic pathogen in periodontal infections. F. nucleatum possesses
several virulence factors, including adhesins (facilitating
adhesion and invasion to various cell types, leading to colonization, dissemination, and triggering host immune
responses) [13], endotoxins (e.g., LPS) [42, 43], and secre-

tion of serine proteases (responsible for suppressing the
nutritional needs of other oral microorganisms) (summarized in Table 2) [44].
There is evidence that synergistic and antagonistic
interactions among various microorganisms inﬂuence the
pathogenesis of PD [45, 46]. P. gingivalis suppresses
apoptosis in gingival epithelial cells by activating the
phosphatidylinositol-3-kinase (PI3K) signaling pathway,
thereby favoring its own survival as well as intracellular
survival of F. nucleatum, as observed in a coinfection subcutaneous chamber model (F. nucleatum and P. gingivalis)
[29]. The interaction between these bacterial species may

4

Mediators of Inﬂammation
Table 2: Virulence factors of Fusobacterium nucleatum.

Periodontopathogenic
pathogen

Virulence factors

Function

Reference

Adhesins
LPS

FadA is required for binding and invasion of host cells
Stimulates inﬂammation and bone resorption
Induces damage to host tissue and IgA degradation
while favoring acquisition of nutrients
Butyrate and ammonium inhibits the
proliferation of gingival ﬁbroblasts
RadD and Fap2 function as adhesins, binding to a
variety of Gram-positive species and Porphyromonas gingivalis,
respectively. Both of them induces lymphocyte apoptosis

[76–78]
[79, 80]

Serine proteases
Fusobacterium
nucleatum

Production of ammonium
and butyrate
Outer membrane proteins
(Fap2 and RadD)

[44]
[81]
[82–84]

FadA: Fusobacterium adhesin A; Fap2: fatty-acid-binding protein.

inﬂuence the mechanism of invasion and adhesion of
these and other periodontal bacteria in human gingival epithelial cells [2]. F. nucleatum was shown to be capable of
increasing the invasion of P. gingivalis in gingival epithelial
cells [2, 47, 48]. In an animal model study, coinfection with
P. gingivalis and F. nucleatum synergistically increased bone
loss and exacerbated inﬂammatory responses when compared to that of monoinfection in rat periodontal tissues
[49]. The consequences of these interactions may be caused
not only by local inﬂammation but also by systemic
manifestations.
In order to carry out studies with periodontopathogenic
bacteria, several bacterial strains are used. The use of bacterial strains from a given type culture is more feasible due to
easy access to commercially available sources, as opposed to
the more diﬃcult collection of bacteria from clinical subjects.
It is important to appreciate that strains of the same bacterial
species may have varying characteristics, and therefore, the
results generated by one strain are not always transferable
to another. It is advisable to use clinical microorganisms
as well as those from collections (type cultures) to conduct
these studies, in order to compare them with their standards. Notably, it was observed that there were no diﬀerences in LPS characteristics and cellular activation when
using clinical samples from patients with periodontitis
and ATCC strains [50].
P. gingivalis strains show genetic variations, and studies
have associated these variations with virulence potential, in
which certain strains present a greater virulence whereas
other strains of the same species display more commensal
behavior [51]. Examples of virulent strains of P. gingivalis
are W83, W50, ATCC 49417, and A7A1, while 381, 33277,
and 23A4 are characterized as less virulent strains [52–54].
Regarding F. nucleatum, it was shown that all strains signiﬁcantly increased the phagocytic capacity of neutrophils as
well as IL-8 and TNF-α production [55]. Interestingly,
phagocytosis of F. nucleatum ss polymorphum was signiﬁcantly greater than that of F. nucleatum ss vincentii and ss
nucleatum [55]. These studies highlight the importance of
choosing the correct strain to perform in vitro and in vivo
studies that mimic the bacterial eﬀects on human oral
diseases.

3. Immunological Mechanisms Triggered by
P. gingivalis and F. nucleatum
Here, we reviewed pathways used by the host to control P.
gingivalis and F. nucleatum infection as well as how these
bacteria subvert these innate and adaptive immune responses.
3.1. Pattern Recognition Receptors (TLR2 and TLR4
pathways). Bacterial components induce innate immune
responses through host recognition to pathogen-associated
molecular patterns (PAMPs), which are evolutionarily
conserved molecules shared by microorganisms, but which
are absent in the host. These PAMPs alert the innate immune
system to the presence of pathogens. In the same context, in a
situation of tissue homeostasis alteration due to microbial
invasion, necrosis, cell injury, or stress, the release of intracellular damage-associated molecular patterns (DAMPs)
occurs. DAMPs are considered danger signals that alarm
the innate immune system and are therefore alternatively
called “alarmins” [85].
PAMPs and DAMPs are identiﬁed by a wide variety of
pattern recognition receptors (PRRs), present in the plasma
membrane, cytoplasm, or vesicles (such as endosomes) in
inﬂammatory cells, as well as in resident cells. The recognition of PAMPs and DAMPs by the host results in the induction of signaling pathways such as activator protein 1 (AP-1)
and factor nuclear kappa B (NF-κB), leading to the expression of proinﬂammatory cytokines [86]. The family of PRRs
includes Toll-like receptors (TLRs), C-type lectin receptors
(CLRs), RIG-I-like receptors (retinoic acid-inducible geneI-like receptors, or (RLRs)), and nucleotide oligomerization
domain- (NOD-) like receptors (NLRs) [86].
TLRs are expressed in oral epithelial tissue, can be stimulated by commensal microorganisms, and also serve to protect the host against microbial infections [9]. The TLR
signaling pathway involves the recruitment of the adapter
protein containing the TIR (Toll-IL-1 receptor) domain
and myeloid diﬀerentiation primary response 88 (MyD88)
to the cytoplasmic region of TLR, with subsequent activation
of NF-κB and induction of proinﬂammatory cytokines and
host defense genes [87].
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Environmental inﬂammation

Hemin levels

Hemin levels

Phosphorylated penta-acylated
lipid A
LPS

Monophosphorylated tetraacylated lipid A

P. gingivalis

LPS
Extracellular

TLR4

TRAM

Extracellular

TRAM

Intracellular

TRIF

P. gingivalis

TLR4

Intracellular
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TRAF 6
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Proinﬂammatory
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Figure 1: Two forms of P. gingivalis lipid A depending on the microenvironment and their interference in TLR4 receptor signaling
downstream activation. Legend: LPS: lipopolysaccharide; p65: nuclear factor NF-κB protein p65 subunit; p50: nuclear factor NF-κB
protein p50 subunit; Rel A: v-rel reticuloendotheliosis viral oncogene homolog A; TLR4: Toll-like receptor-4; TRAF 6: tumor necrosis
factor receptor-associated factor 6; TRIF: TIR-domain-containing adapter-inducing interferon-β; TRAM: TRIF-related adaptor molecule.

The interaction of LPS with TLRs is one of the mechanisms of manipulation of the host response used by P. gingivalis to facilitate its adaptation and survival [88]. LPS is
composed of an antigen O of variable length, a polysaccharide core, and a lipid A moiety. Lipid A is the eﬀector LPS
portion that binds to TLR4/MD2/CD14 (TLR4 signaling
requires additional costimulation by cluster of diﬀerentiation
14 (CD14) and myeloid diﬀerentiation protein 2 (MD-2)).
The molecular structure of LPS varies depending on the bacterial species [89]. The level of acylation of PAMPs allows the
host to discriminate commensal from pathogenic bacteria
[90]. P. gingivalis LPS diﬀerentiates from LPS of other bacterial species through modiﬁcations in the O-antigen structure
[91–93], as well as modiﬁcations in the acylation patterns
and in the receptor-activating capacities of the lipid A component [11]. Lipid A from P. gingivalis has a penta-acylated
phosphorylated structure that activates TLR4 and a tetraacylated monophosphorylated structure that antagonizes
TLR4, thereby attenuating host immune responses. These
diﬀerences of lipid A structures depend on the microenvironment and hemin concentrations [94]. At high hemin concentrations, conferring high degrees of inﬂammation, several
tetra- and penta-acylated lipid A structures were observed
in P. gingivalis as opposed to one major penta-acylated lipid
A structure at low hemin levels [94] (see Figure 1). Another
type of LPS was also identiﬁed in P. gingivalis, A-LPS, with
an anionic polysaccharide linked to lipid A, responsible for
serum resistance and cellular integrity; however, it was a

weak inducer of cytokine release by human monocytes [91].
The literature remains conﬂicted regarding signaling of P.
gingivalis LPS binding to TLR2/4 receptors; this conﬂict concerns the distinct portions of P. gingivalis lipid A that exhibit
various receptor binding attributes [88].
F. nucleatum lipid A is a hexa-acylated fatty acid composed of tetradecanoate (C14) and hexadecanoate (C16)
and is structurally similar to Escherichia coli lipid A [95]. This
structural similarity may explain the fact that F. nucleatum
has a strong activity via TLR4 [95] (see Figure 2). These
structural diﬀerences in bacterial LPS composition may
explain why F. nucleatum LPS stimulates IL-1β secretion
more strongly than does P. gingivalis LPS [96].
The observations cited above explain why TLR2 predominates over TLR4 in terms of recognition by P. gingivalis [36].
Activation of TLR2 by P. gingivalis LPS induces two distinct
signaling pathways, one of which leads to the synthesis of
proinﬂammatory cytokines, and antimicrobial responses
and represents the pathway of CXC chemokine receptor 4
(CXCR4) modulated by P. gingivalis. The other cascade
involves the proadhesive capacity and pathway crosstalk
between TLR2 and the complement system [36]. It has been
demonstrated in vivo and in vitro in neutrophils that P.
gingivalis inhibits the TLR2/MyD88 signaling which is
considered a host-protective pathway, thus avoiding the
death of neutrophils infected with P. gingivalis. This inhibition occurs through ubiquitination and degradation of
MyD88 via E3 ubiquitin ligase Smurf1 dependent of the
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Figure 2: Structural chemical diﬀerences in lipid A of F. nucleatum and P. gingivalis and their interaction with TLR4. Legend: MyD88:
myeloid diﬀerentiation primary response 88. TLR4: Toll-like receptor-4; -: antagonize TLR4 activation; +++: strong TLR4 agonistic response.

crosstalk between TLR2 and the complement receptor
C5aR (C5aR/TLR2). On the other hand, P. gingivalis activates the TLR2/Mal/PI3K signaling pathway that blocks
phagocytosis and stimulates inﬂammation in neutrophils
[29, 97]. Because of the eﬀects of P. gingivalis gingipains during infection with this pathogen, there are high levels of C5a
[97, 98] that could induce alteration of the PI3K pathway
leading to inhibition of phagocytosis. The C5aR/TLR2 crosstalk generated by P. gingivalis inhibits the activation of RhoA
(Ras homolog gene family, member A), cytoskeleton reorganization, and actin polymerization, all of which contribute to
phagocytosis. All these eﬀects result in a protective eﬀect, not
only for P. gingivalis but also for other bacteria of the oral
cavity. These modulations by P. gingivalis contribute to the
persistence of periodontal dysbiosis and the chronicity of
inﬂammation in PD [29].
The crosstalk between the TLR2 and the CXCR4 in lipid
rafts of macrophages is another form of subversion of the
immune response by P. gingivalis, allowing their survival
in vivo and in vitro. The ﬁmbriae of P. gingivalis bind to
CXCR4 and activate the cAMP-dependent protein kinase A
pathway, inhibiting NF-κB and nitric oxide (NO) synthesis
[67]. For this reason, ﬁmbriae from P. gingivalis are considered molecules with antimicrobial properties [67].
P. gingivalis induces the release of IL-1, IL-6, IL-8, and
TNF-α, promoting inﬂammatory responses via TLR4/TLR2
in host cells [10, 99–101]. We demonstrated that the induction of IL-1β mRNA and protein depended on the activa-

tion of TLR2 and MyD88 in murine macrophages; the
absence of ﬁmbriae did not aﬀect this stimulus (Morandini
et al., 2014), although it is known that the ﬁmbriae of P.
gingivalis activate TLR2, among others, including phosphoceramides and PG1828 lipoprotein [50]. This was
observed in the work of Asai et al., in which P. gingivalis
ﬁmbriae stimulated the expression of IL-8 in gingival
epithelial cells via TLR2 [102].
P. gingivalis ﬁmbriae induce the production of proinﬂammatory cytokines, including IL-6 and TNF-α, and they
mediate the expression of adhesion molecules, including
intercellular adhesion molecule 1 (ICAM-1) [103]. The ﬁmbriae exploit TLR2 signaling to interact with complement
3 (CR3), thereby allowing internalization of P. gingivalis
into macrophages [104]. This virulence factor reduces the
production of IL-12 that may inhibit bacterial clearance
and lead to an increase of adhesion of CR3-dependent
monocytes to vascular endothelium and transendothelial
migration [105].
Both TLR2 and TLR4 are associated with bone loss in
an animal model of periodontitis induced by P. gingivalis
[106–108]. The phosphoglycerol dihydroceramide (PGDHC)
from P. gingivalis also promotes receptor activator of nuclear
factor kappa-Β ligand- (RANKL-) mediated osteoclastogenesis, via interaction with Myh9 (nonmuscle myosin II-A) independently of TLR2/4 [72].
During F. nucleatum infection in macrophages, both
TLR2 and TLR4 recognize this pathogen and are redundant
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Figure 3: Immune response pathways triggered by the activation of TLR2/TLR4 by F. nucleatum and P. gingivalis bacteria and possible
therapeutic targets. Legend: CXCR4: C-X-C chemokine receptor type 4; cAMP: cyclic adenosine monophosphate; iNOS: inducible
nitric oxide synthase; Mal: MyD88 adapter-like; p38MAPK: mitogen-activated protein kinase p38; PKA: protein kinase A; PI3K:
phosphoinositide-3-kinase; RhoA: Ras homolog gene family, member A.

in terms of the production of IL-6 and TNF-α [109]. In
macrophages, MyD88 is required for cytokine secretion
induced by F. nucleatum infection [109]. Furthermore,
the same study showed that TLR2/TLR4 and MyD88 were
required for the optimal activation of NF-κB and mitogenactivated protein kinases (MAPKs, including p38, extracellular signal-regulated kinase (ERK), and Jun N-terminal
protein kinase (JNK)) in response to F. nucleatum [109].
Interestingly, using HEK293T cells, which lack endogenous
TLRs, it was demonstrated that F. nucleatum induced IL-8
secretion [110]. In that study, F. nucleatum invasion in the
host cell was needed to induce IL-8 secretion, as was p38
MAPK signaling, but not NF-κB or NOD-1 [110]. On the
other hand, TLR2-silenced Ca9-22 cells infected with F.
nucleatum resulted in the absence of IL-6 and IL-8
responses, whereas induction of IL-1β remained, suggesting
that this bacterium modulates the expression of these cytokines via TLR2 [90].
Antimicrobial peptides, including human beta-defensins
(HBD), assist the barrier function of gingival tissue [111]. F.
nucleatum increased the expression of the HBD-2 and
HBD-3, and it is believed that this induction occurs via
TLR2, considering that there was suppression of F. nucleatum-induced HBD when using TLR2 knockdown cells
[112]. Furthermore, FomA, a porin protein from F. nucleatum, was shown to induce cytokine secretion through TLR2
signaling [112].
Therefore, it is important to understand the TLR2 and
TLR4 downstream signaling pathways induced by oral bacte-

ria in cells of the oral cavity and in animal models of PD,
because they can potentially be targets of pharmacological
treatments. Therapeutic drugs could be designed to target
the inhibition of the signaling pathways used by P. gingivalis
and F. nucleatum to survive, as suggested in Figure 3.
3.2. Inﬂammasomes. NLRs (nucleotide-binding oligomerization domain-like receptors) are part of the family of PRRs
and can be a part of “inﬂammasomes” [86, 113, 114]. Inﬂammasomes are multiprotein complexes assembled in the host
cell in response to infection and/or cellular stress that can
ultimately lead to a type of cell death called “pyroptosis”
and/or proinﬂammatory cytokine maturation and secretion
[19, 115]. Canonical inﬂammasomes activate procaspase-1
into the mature form caspase-1 while noncanonical inﬂammasomes involve caspase-11 (in mice) or caspase-4/5 (in
humans) [21]. Canonical inﬂammasomes can be activated
by various ligands, and they are named according to the
receptor involved in the stress recognition: NLPR3, NLRP1,
NLRC4, and AIM2. By contrast, noncanonical inﬂammasomes are only activated by cytosolic LPS [21]. In the case
of the NLRP3 and AIM2 inﬂammasomes, a PYD-CARD
adaptor protein ASC (apoptosis-associated protein with
caspase recruitment domain) is required for the assembly
and stabilization of these inﬂammasomes, as reviewed elsewhere [21, 115].
NLRP3 is currently the best characterized inﬂammasome
and is associated with various chronic inﬂammatory diseases,
including type II diabetes, obesity, and intestinal diseases
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[116]. It is well accepted that two signals are needed to
activate the NLRP3 inﬂammasome: (1) the recognition of
a PAMP via PRRs such as TLRs induces NF-κB activation
and subsequent transcription of genes encoding NLRP3
and inactive forms of the proinﬂammatory cytokines,
including pro-IL-1β and pro-IL-18 [21, 115]; and (2) crystals/particles (such as uric acid and silica), β-amyloid, bacteria,
viruses, fungi, protozoa, pore-forming toxins, and DAMPs
such as adenosine triphosphate (ATP) [23, 115, 117] are
recognized by the host cell and activate the inﬂammasome
[115]. Activation of the NLRP3 inﬂammasome results in
the activation of caspase-1 that is responsible for cleaving
pro-IL-1β and pro-IL-18 to their biologically active forms,
IL-1β and IL-18 and/or for inducing pyroptosis (to be
discussed later in this review [115]). Recent studies showed
that activated caspase-1 cleaves gasdermin D, inducing
pore formation in the plasma membrane and leading to
IL-1β/IL-18 release and/or pyroptosis [118, 119].
Studies have examined inﬂammasome components and
their byproducts during periodontitis and infection of cells
with periodontopathogens. Human monocytic cells (MonoMac-6 cells) infected with P. gingivalis showed increased
levels of NLRP3 and IL-1β/IL-18 but decreased levels of
ASC [120]. In THP-1 cells, P. gingivalis activated the NLRP3
inﬂammasome through the TLR2 and TLR4 pathways [121].
This bacterium may downregulate ASC as a mechanism of
survival, because ASC is involved in cell death and consequent clearance of intracellular bacteria [122].
We and others demonstrated that P. gingivalis infection
induced intracellular pro-IL-1β production but not IL-1β
secretion in human gingival epithelial cells [123] and murine
macrophages [20, 96, 124]. In fact, in human gingival epithelial cells and murine macrophages, we and others showed
that purinergic P2X7 receptor activation by extracellular
ATP is necessary for IL-1β release after P. gingivalis infection
[20, 96, 123, 124]. Furthermore, we found that the intracellular processing of pro-IL-1β was NLRP3-dependent in
murine macrophages [124]. Alternatively, some studies
have shown that caspase-8 can also be involved in NLRP3
inﬂammasome activation and cleaved pro-IL-1β in response
to TLR4 activation [125, 126].
Furthermore, we showed P. gingivalis infection in vivo
induced IL-1β production in order to restrain bacterial
infection in a manner that was dependent on caspase1/11, P2X7 receptor, and autocrine IL-1 receptor signaling
[20]. Interestingly, it was showed that P. gingivalis mediated
inﬂammasome repression when macrophages were coinfected with P. gingivalis and F. nucleatum through a mechanism involving reduced endocytosis [96]. These studies
highlight the importance of studying infection models in
order to understand the pathogenesis and immune responses
during periodontitis.
In fact, the inﬂammasome is very important in the pathophysiology of periodontitis. It is already known that the
NLRP3 inﬂammasome [18] and secretion of IL-1β [68] are
crucial for the development of PD, because in the absence
of NRLP3 or IL-1β, there is no periodontitis induced by
P. gingivalis in mouse models. IL-1β also plays a prominent role in promoting tissue pathology and inﬂammatory
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responses in periodontal lesions and stimulating the loss of
connective tissue and bone [68]. Furthermore, various studies demonstrated increases in the expression of NLRP3,
AIM2, IL-1β, and IL-18, but not ASC or NLRP2, in gingival
tissue from periodontitis patients when compared to healthy
individuals [120, 121, 127].
Unlike P. gingivalis infections, in murine macrophages
and gingival epithelial cells, F. nucleatum infections activate
the NLRP3 inﬂammasome leading to pyroptosis and IL1β/IL-18 secretion even in the absence of extracellular ATP,
suggesting that F. nucleatum provides both PAMPs and a
danger signal [96, 128]. In gingival epithelial cells, F. nucleatum leads to NF-κB activation, culminating in enhanced
expression of the proinﬂammatory cytokine IL-8 [129] and
IL-1β secretion [128]. In these cells, F. nucleatum infection
was suﬃcient to induce caspase-1 activation in a NLRP3dependent manner and the secretion of the danger signals
ASC and high-mobility group box 1 protein (HMGB1)
[128]. Interestingly, we showed that NLRX1 has a dual eﬀect
on F. nucleatum-infected gingival epithelial cells by upregulating NLRP3-dependent caspase-1 activation but downregulating NF-κB activation and IL-8 production [129]. These
results show that inﬂammasome activation after F. nucleatum infection is a robust but complex regulated process. In
oral infection in mice, we showed that F. nucleatum induced
the expression and secretion of several proinﬂammatory
cytokines, including the inﬂammasome-dependent IL-1β
[130]. In agreement with in vitro and mouse model studies,
the expression of the components of the NLRP3 inﬂammasome was also shown to be increased in periapical lesions
in human subjects with periapical periodontitis [131].
Despite the fact that F. nucleatum infection in vivo was
evaluated in some studies, the eﬀects of this bacterial
infection in vivo with respect to inﬂammasome activation
and modulation still needs to be investigated, because it
may be an important therapeutic target.
Regarding inﬂammasomes other than the NLRP3, it was
demonstrated that NLRP6 was more highly expressed in
gingival tissues of patients with periodontitis than in healthy
controls [132]. The same study showed that pyroptosis of
gingival ﬁbroblasts induced by P. gingivalis infection was
dependent on the NLRP6 inﬂammasome and caspase-1
activation. Moreover, P. gingivalis-infected gingival ﬁbroblasts showed increased levels of IL-1β and IL-18 secretion
in an NLRP6 and caspase-1-dependent manner [132]. Furthermore, the expression of the AIM2 inﬂammasome (that
recognizes double-stranded DNA) was also more highly
expressed in the gingival tissue of periodontitis patients
than in controls, as well as in human macrophages
infected with P. gingivalis [121]. In human macrophages,
P. gingivalis induced pyroptosis and IL-1β secretion in a
caspase-1/AIM2 inﬂammasome-dependent manner [121].
In agreement with these studies, the AIM2 inﬂammasome
was also found in high levels in periapical lesions and was
primarily distributed in inﬂammatory cells [131]. These
data suggest that the AIM2 and NLRP6 inﬂammasomes
are involved in the development of PD, highlighting the
need to study these immunological pathways during these
diseases and periodontopathogen infections, in order to
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develop therapeutic targets. Together, these data using cell
lines, mouse models, and clinical samples demonstrate that
inﬂammasomes play important roles in the pathophysiology of periodontitis as well as during control of P. gingivalis and F. nucleatum infections. This supports the concept
that inﬂammasome components and/or its byproducts
could be potential therapeutic targets for modulating the
development of periodontitis and/or controlling infection
by periodontopathogens.
3.3. Purinergic Signaling. ATP acts as a signaling molecule in
various physiological processes, including synaptic transmission, bone formation and resorption, blood pressure regulation, and inﬂammation [133–135]. Extracellular nucleotides
bind to purinergic receptors [136], and these receptors and
their subtypes are found in virtually all cell types in mammals
[137]. As mentioned above, extracellular ATP is considered a
DAMP that can be released from stressed/damaged, infected,
or dying cells via various proposed mechanisms, including
pannexin-1 hemichannels, connexin hemichannels, or even
through the purinergic P2X7 receptors, with consequent
autocrine and paracrine cell signaling [138–142].
Purinergic receptors are classiﬁed as P1 and P2 receptors
[136]. P1 receptors are G-protein-coupled metabotropic
receptors that exclusively recognize extracellular adenosine
[143, 144]. Their role during periodontopathogen infections
will be discussed later in this review. There are two subfamilies of purinergic P2 receptors: P2X receptors that are ionic
channels activated by ATP and P2Y receptors that are Gprotein-coupled receptors activated by ATP, ADP, UTP,
UDP, and UDP-glucose [143, 145]. Currently, seven P2X
receptors (P2X1–P2X7) and eight P2Y receptors (P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) are
known [136, 145]. Among these receptors, the P2X7 receptor has been shown to regulate inﬂammatory processes
that mediate cell death and elimination of intracellular
infectious microorganisms; its expression is regulated by
inﬂammatory cytokines [146]. It has been associated with
immune responses and inﬂammation [139, 147, 148],
including immune responses against P. gingivalis, as we
reviewed elsewhere [19].
We showed that P. gingivalis infection induces higher
expression of the P2X7 receptor in infected murine macrophages [124] and in the maxilla of orally infected mice [17].
Corroborating our data in mice, we also demonstrated that
P2X7 receptor expression levels were lower in patients after
conventional periodontal treatment than prior to treatment
[17], suggesting that the P2X7 receptor may play a role
during PD and infection. Interestingly, P2X7 receptor distribution in macrophages may be modulated by P. gingivalis
ﬁmbriae, because we showed that receptor expression
had a distinct pattern of focus formation in the absence
of P. gingivalis ﬁmbriae [124]. These data suggest that P.
gingivalis infection induces P2X7 receptor expression and
that P. gingivalis expresses virulence factors that allow this
pathogen to modulate receptor distribution in the host cell.
In a model of P. gingivalis infection in vivo, we showed
that the P2X7 receptor was required for IL-1β production,
leukocyte recruitment to the site of infection, and bacterial
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clearance [20]. Interestingly, the P2X5 receptor was shown
to be required for eﬃcient production of IL-1β and osteoclast
maturation in vitro, and that P2X5 receptor deﬁciency, but
not P2X7 receptor deﬁciency, led to decreased bone loss in
an animal model of PD [149]. These data suggest that the
P2X7 receptor might be dispensable for the development of
periodontitis but it is required for the induction of immune
responses and microbial clearance during periodontogenic
bacterial infection in murine models. Together, these results
suggest that the P2X5 and P2X7 receptors may be novel
therapeutic targets in this oral disease.
The ability of P. gingivalis to adapt to the gingival epithelium has not yet been fully understood. Among several virulence factors harbored by P. gingivalis, it seems that this
pathogen evolved to protect itself against extracellular ATP
through its nucleotide-diphosphate-kinase enzyme (NDK).
NDK is an important virulence factor of P. gingivalis that
has been shown to cleave extracellular ATP molecules
[150]. After P. gingivalis infection in gingival epithelial cells,
release of ATP occurs and the P2X7/pannexin 1 receptor is
activated by autocrine action of ATP; the NDK from P.
gingivalis accumulates in the cytoplasm [151]. NDK from
P. gingivalis is carried along myosin-9 ﬁlaments and actin
ﬁlaments to the host cell periphery. Upon translocation to
the extracellular environment through the formation of the
P2X7/pannexin 1 channel, NDK hydrolyzes ATP, thereby
reducing the activation signal of the P2X7 receptor and
its downstream signaling events [151]. During infection
in gingival epithelial cells, NDK from P. gingivalis inhibited
ATP-induced reactive oxygen species (ROS) generation,
thereby contributing to bacterial persistence [152]. NDK also
decreased ATP-induced IL-1β release [153] and inhibited
ATP-induced host cell death after infection with P. gingivalis
[150]. Inhibition of these pathways by P. gingivalis, by means
of its NDK, contributes to intracellular bacterial survival and
persistence [151].
P. gingivalis also modulates the transcription of forkhead
box protein 1 (FOXO-1) genes, leading to the synthesis of
antioxidant enzymes such as superoxide dismutase and catalase, restoring the redox balance and preventing long-term
oxidative damage. With the inhibition of the toxic response,
P. gingivalis can survive, replicate, and translocate through
adjacent cells, notwithstanding its ability to adapt to the
oxidative stress environment [152, 154]. Intracellular P.
gingivalis inhibited NADPH oxidase (NOX) 2-ROS,
followed by suppression of hypochlorous acid production
in gingival epithelial cells; these bacteria were present in
ER-rich/LC3-positive autophagic vacuoles, considered a
new mechanism of bacterial survival [24].
P1 receptors recognize extracellular adenosine; they are
subdivided into A1, A2a, A2b, and A3, exhibiting varying
degrees of sensitivity to adenosine [155]. During gingival epithelial cell infection with P. gingivalis, treatment with the speciﬁc A2a receptor agonist (CGS-21680) led to bacterial
proliferation and increased cAMP levels. However, when a
broad-spectrum adenosine agonist (NECA) was used, minimal eﬀects on intracellular P. gingivalis levels were observed
[156]. These data suggest that adenosine signaling may
attenuate inﬂammatory processes associated with bacterial
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Figure 4: Activation of purinergic P2X7 receptor and inﬂammasome by the bacterium F. nucleatum or P. gingivalis and possible
therapeutic targets.

infection [156], a mechanism of bacterial survival in the buccal mucosa. These results demonstrate the need for further
studies aimed at the participation of P1 and P2 receptors in
the context of infection by periodontopathogenic bacteria,
as well as PD. Furthermore, even though there are no studies
of purinergic signaling and F. nucleatum to date, the results
from our group and others on P. gingivalis infection suggest
that F. nucleatum infection can also be modulated by purinergic signaling infection. In this context, future studies are
needed regarding F. nucleatum infection and purinergic signaling. Figure 4 suggests therapeutic targets in the pathways
of the activation of purinergic P2X7 receptor and inﬂammasome by the bacteria F. nucleatum and P. gingivalis.
3.4. Regulation of Caspases Involved in Apoptosis and
Pyroptosis by P. gingivalis and F. nucleatum. Caspases are
endoproteases that cleave peptide bonds in a cysteinedependent and aspartate-directed manner [157]. Caspases
can mediate substrate activation and inactivation, and they
may also generate active signaling molecules that participate
in immune responses, including cell death and inﬂammation
[157]. To date, 11 caspases have been found in humans
(caspase-1 to caspase-10 and caspase-14), whereas 10 have
been found in mice (caspase-1, 2, 3, 6, 7, 8, 9, 11, 12, and
14) [157]. Caspases are categorized according to their roles
in physiology: apoptosis (caspase-3, 6, 7, 8, and 9 in mammals) and inﬂammation/pyroptosis (caspase-1, 4, and 5 in
humans and caspase-1 and 11 in mice).
Caspase-11 has a protective eﬀect during infections in
which the bacterium invades the cytosol [158]. This caspase

directly binds the hexa-acylated lipid portion of LPS from
Gram-negative bacteria, the same component structure that
activates TLR4, through its CARD domain [22]. However,
species with four acyl groups, although capable of binding,
have not been shown to activate caspase-11 [159]. There
are some pathogenic bacteria that alter the acylation status
of its lipid A, thereby avoiding recognition by cells of the
immune system, minimizing the inﬂammatory process [22].
In this context, it is important to carry out studies that evaluate the possibility of caspase-11 controlling the intracellular
proliferation of P. gingivalis and F. nucleatum.
Apoptosis is a programmed cell death that involves the
controlled dismantling of intracellular components while
avoiding inﬂammation and damage to surrounding cells
[157]. By contrast, pyroptosis is a nonapoptotic type of cell
death that involves plasma membrane rupture and release
of proinﬂammatory intracellular contents [160]. For this reason, pyroptosis usually occurs via noncanonical inﬂammasome activation by Gram-negative bacteria and is mediated
by inﬂammatory caspase-1 and caspase-4/5 in humans, or
by caspase-1 and caspase-11 in mice [118, 119]. Pyroptosis
is characterized by the formation of membrane pores, cell
edema, and osmotic lysis and release of the cytosolic contents
into the extracellular medium [22]. This pathway contributes
to intracellular bacterial clearance and destroys any niche
formed by intracellular bacterial replication because it causes
intracellular bacterial exposure to the extracellular compartment, making bacteria more susceptible to antibodies and
attacks by phagocytes such as neutrophils [159]. In this sense,
it is advantageous to prevent or delay host cell death in order
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to preserve their intracellular environment, thereby favoring
microbial persistence [19].
Induction or inhibition of apoptosis by bacteria varies
according to cell type, bacterial species and strains, duration
of infection, and presence of bacterial components (e.g.,
LPS, proteinases). Cell death by P. gingivalis was observed
in B cells and human gingival ﬁbroblasts, and inhibition of
apoptosis provoked by this bacterium was demonstrated in
human monocytes, macrophages, neutrophils, and primary
gingival epithelial cells [161–168]. One of the pathways in
which P. gingivalis prevents the death of gingival epithelial
cells either by necrosis or by apoptosis is through the activation of the JAK1/Akt transducer and transcriptional activator
3 (STAT3) pathway, causing upregulation of miR-203 that
leads to inhibition of the suppressor of cytokine signaling 3
(SOCS3) negative regulator and subsequent suppression of
apoptosis [168–170]. Furthermore, at the mitochondrial
membrane, proapoptotic Bad is inhibited and the ratio of
Bcl2 : Bax increases, decreasing cytochrome c levels and caspase-3/9 activation, thereby reducing the eﬀect of apoptosis
[171].
During infection in murine macrophages, we and others
showed that P. gingivalis itself did not induce the expression
of the activated form of caspase-1, pyroptosis [70], and IL-1β
[17, 20, 70, 96, 124], requiring a second signal for the activation of these molecules ([17, 20, 96, 124]). However, OMVs
isolated from P. gingivalis induced the activation of
caspase-1 (including pyroptosis) and IL-1β in murine and
human macrophages [70], suggesting that live P. gingivalis
negatively modulates inﬂammasome and caspase-1 activation in favor of its own survival. By contrast, studies using
PMA-primed THP-1 cells demonstrated that P. gingivalis
infection per se induced the activation of the NLRP3 and
AIM2 inﬂammasomes, promoting caspase-1 [121] and
caspase-4 activation, leading to pyroptosis in a MOIdependent manner [172]. Interestingly, high levels of P.
gingivalis infection did not induce caspase-1 activation or
cell death due to a mechanism believed to involve gingipains [70, 173]. Therefore, P. gingivalis can modulate activation of caspases involved in apoptosis and pyroptosis
depending on the cell line and model of infection. These
data agree with those of a study showing enhanced levels
of NLRP3 and pyroptosis along with the active forms of
caspase-1 and IL-1β in the gingival stroma of periodontitis
specimens compared to those of healthy samples [174].
In vitro studies showed that while P. gingivalis can persist
intracellularly in macrophages for up to 63 h [175], this
bacterium was able to survive intracellularly for up to 8 days
in gingival epithelial cells [73]. Indeed, P. gingivalis possesses
several virulence factors that inhibit host cell death induced
by various proapoptotic agents [168, 169]. P. gingivalis
triggered rapid and reversible surface phosphatidylserine
exposure (an apoptosis marker) through a mechanism
requiring caspase activation [168]. This opportunistic pathogen can manipulate the host machinery to facilitate its longterm survival by inhibiting the intrinsic apoptotic pathway
(cytochrome c release and caspase-3/9 activation) [168,
171]. In fact, it was demonstrated that P. gingivalis inhibited
chemically induced apoptosis in primary cultures of gingival
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epithelial cells by blocking the activation of the eﬀector
caspase-3 via manipulation of the JAK/STAT pathway that
controls intrinsic mitochondrial cell death pathways [169].
Even though P. gingivalis does not induce pyroptosis in
murine macrophages, F. nucleatum infection induces
caspase-1 and pyroptosis that is inhibited if P. gingivalis is
added to the culture [96]. Together, these studies show
that P. gingivalis is well adapted to survive in various cell
types by avoiding the induction of host cell death. These
data suggest the need for studies to verify how these bacteria modulate caspases in favor of their own survival, to
develop therapeutic targets, and to generate eﬀective treatments for PD.
3.5. Adaptive Immunity. The adaptive immune system acts in
the context of the chronicity of PD, reinforcing the protection of the host through cellular and noncellular mechanisms
[176]. During the development of periodontitis, various T
helper subsets predominate in several stages [177]. B cells
were observed to predominate in the progression of periodontal lesions, together with Th2 cell proﬁles [178, 179]. B
cells and their antibodies act by preventing bacterial adhesion, by inactivating bacterial toxins, and by acting as opsonins for neutrophil phagocytosis [180].
CD4+ T cells are involved directly and indirectly in osteoclastic reabsorption during PD. Various subsets of CD4+ T
cells promote or suppress immune responses of the host during the progression of periodontitis [181, 182]. Baker et al.
demonstrated that animals without MHC-II-restricted
CD4+ T cells but not MHC-I-restricted CD8+ T cells were
resistant to oral alveolar bone loss induced by P. gingivalis
infection, suggesting that CD4+ T cells contribute to bone
demineralization [183]. Throughout the development of
periodontitis, Th1 and Th2 responses characterize disease
progression [184], acting as essential immunoregulators
and mediators of the initial lesion. Th17 cells may directly
or indirectly exacerbate inﬂammation by modulating Th1
cells or by increasing the synthesis of inﬂammatory molecules from gingival ﬁbroblasts [185]. By contrast, Treg cells
act on the balance of periodontal lesions and become a therapeutic target, allowing the modulation of host immune
response, thereby attenuating the tissue damage associated
with periodontitis [186]. P. gingivalis stimulates increased
production of the proinﬂammatory cytokine IL-17 produced
by Th17 cells [187] that act by stimulating the production of
inﬂammatory molecules such as cytokines, chemokines, and
other eﬀector compounds, inducing RANKL by osteoblasts,
thereby inﬂuencing reabsorption of bone [188].
P. gingivalis and F. nucleatum also induce and evade
various adaptive immune responses generated in the infected
host. P. gingivalis was shown to suppress IFN-γ-stimulated
release of CXCL9, CXCL10, and CXCL11 from epithelial
cells. The inhibition of chemokine expression occurred at
the level of gene transcription and was associated with
downregulation of interferon regulatory factor 1 (IRF1) and
decreased STAT1 expression [189]. In accordance with
this idea, P. gingivalis-stimulated antigen-presenting cells
enhanced Th17 but not Th1 polarization because the bacteria favored the generation of Th17-related cytokines such
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as IL-1β, IL-6, and IL-23, but not the Th1-related IL-12
[190]. Furthermore, when mice were subcutaneously vaccinated with formalin-killed P. gingivalis and then were orally
challenged with P. gingivalis, the vaccination protected the
mice from alveolar bone resorption and inﬂammation. This
was due to the downregulation of Th17 immune responses
and upregulation of Treg, IL-10, and TGF-β production
[182]. Regarding the production of the T cell growth factor
IL-2, P. gingivalis targets its expression at the protein level
by inhibiting AP-1 and NF-κB activity, impeding the ability
of T cells to sustain stable IL-2 accumulation by means of
the bacterial gingipain Rgp [191]. Interestingly, P. gingivalis
gingipain Kgp was also demonstrated to hydrolyze IgG1
and IgG3 heavy chains in vitro [192]. Moreover, cleavage
of IgG1 was identiﬁed in gingival crevicular ﬂuid from
patients with aggressive periodontitis and chronic periodontitis, while no cleavage was detected in healthy controls
[193]. In a study involving individuals with untreated and
successfully treated chronic periodontitis, both individuals
expressed sIgA, IgA, IgG1, and IgG4 against F. nucleatum
at the same levels but untreated individuals presented sIgA
and Th1- (IFN-γ- and IgG1-) dominant immune responses
[194].
Further studies are needed, primarily in vivo, to evaluate
the role of P. gingivalis and F. nucleatum in the proﬁles of
immunoinﬂammatory cells, correlating them with the
chronicity of PD such that eﬀective treatments may be
developed to prevent the exacerbation of the tissue injury
and bone loss. Figure 5 demonstrates the results discussed
in this review.

4. Challenges and Perspectives
The role of P. gingivalis and F. nucleatum in the pathogenesis
of PDs is well-documented in the literature; nevertheless, the
exact molecular mechanisms induced by these bacteria are
not yet fully understood. Studies on TLR2/4 activation by
P. gingivalis LPS remain to be clariﬁed, because of controversies in the literature. Additional studies in human cells are
necessary because the inﬂammatory potential is higher in
these cells than in animal cells. Further studies are also
needed to investigate how F. nucleatum manipulates downstream TLR2/TLR4 pathways in order to survive and replicate intracellularly. It is known that inﬂammasomes are
involved in the pathogenesis of periodontitis; however, it
remains necessary to determine which inﬂammasomes, in
addition to NLRP3, actually contribute to the pathogenesis
of PD induced by P. gingivalis and F. nucleatum. Even though
we know that P2X7 receptor is involved in the immune
responses against P. gingivalis, the role of the purinergic
signaling in the context of F. nucleatum infection remains
unknown. Further research needs to address the role of
caspases, especially caspase-11, in the context of inﬂammation and cell death in in vivo and in vitro models of PD.
More studies that clarify the diﬀerences in the immune
response of various cells of the oral cavity involved in
infections by P. gingivalis and F. nucleatum are also
needed, considering time of infection, MOI, and types of
strains to be representative in PD in humans. Because
models of coinfections and cocultures are more representative of human periodontitis, it is important that future
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studies investigate models of in vivo coinfection with P. gingivalis and F. nucleatum in order to better understand the
host immune response. Therefore, with more solid literature
on these signaling pathways and immune responses during
infection with these bacteria, eﬀective treatments for PD
may emerge.
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